Gilead Stock News

Kite Pharma , a Gilead Science Inc''s Company (NASDAQ: GILD ), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene ciloleucel) as a one-time infusion. The head-to-head study evaluated Yescarta against standard of care (SOC) for adults with large B-cell lymphoma (LBCL) who relapsed or were refractory to first-line treatment. With a median follow-up of over two years, the study met the primary endpoint of event-free survival. Yescarta demonstrated a 2.5 fold increase in alive patients at two years Full story available on Benzinga.com

Jaffetilchin Investment Partners LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 4,104 shares of the biopharmaceutical company’s stock, valued at approximately $287,000. Several other institutional investors also recently bought and sold shares of the company. Redwood Investment Management LLC boosted its […]

The global Antifungal Agents market was valued at 1116.22 Million USD in 2020 and will grow with a CAGR of 2.71% from 2020 to 2027. The report covers the key players of the industry including Company Profile, Product Specifications, Production

Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene ciloleucel) as a one-time infusion. The head

Gilead Sciences, Inc. (NASDAQ:GILD) with the stream of -0.07% also noticed, India Eros STX Global Corporation (NYSE:ESGC) encountered a rapid change of 1.11% in the last hour of Fridays trading The post Project Future Performance Before Investment: Gilead Sciences, Inc. (NASDAQ:GILD), Eros STX Global Corporation (NYSE:ESGC) appeared first on Stocks Equity .

These stocks may suit the value investor Check out Joel Greenblatt Stock Picks » Download GuruFolio Report of Joel Greenblatt (Updated on 12/11/2021) Related Stocks: TSN , NRG , GILD ,

Janney Montgomery Scott LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 223,822 shares of the biopharmaceutical companys stock after selling 7,325 shares during the quarter. Janney Montgomery Scott LLCs []

Investors may want to consider the following non-cyclical stocks, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are outperforming the 20-year high quality m

TCW Group Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 673,377 shares of the biopharmaceutical companys stock after selling 6,725 shares during the quarter. TCW Group []

(RTTNews) - Kite, a Gilead Company (GILD), said that yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma. The primary analysis of ZUMA-7, a global Phase 3 study evaluating Yescarta (axicabtagene ciloleucel) as a one-time infusion, in a

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL). Among all patients treated with Yescarta, the five-year overall survival (OS) rate was 42.6% (95% CI, 32.8 51.9). Among patients who had a complete response (CR), the five-year OS rate was 64.4% (95% CI, 50.8 75.1) and median survival time has

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult pa

Wall Street analysts forecast that Gilead Sciences, Inc. (NASDAQ:GILD) will report earnings per share of $1.45 for the current quarter, according to Zacks. Seven analysts have made estimates for Gilead Sciences earnings. The highest EPS estimate is $1.80 and the lowest is $1.21. Gilead Sciences reported earnings per share of $2.19 in the same quarter []

Gilead Sciences Inc. (NASDAQ:GILD)’s traded shares stood at 1.17 million during the latest session, with the company’s beta value hitting 0.35. At the last check today, the stock’s price was $69.91, to imply a decrease of -0.55% or -$0.39 in intraday trading. The GILD share’s 52-week high remains $73.34, putting it -4.91% down since that … There Has Been A -0.55% Decline For Gilead Sciences Inc. (NASDAQ: GILD). So What’s Next? Read More »

Gilead Sciences (GILD) closed the most recent trading day at $70.25, moving -0.07% from the previous trading session.